|
| |
| |
| |
Are You Ready to Take HIV Prevention to Another Level? |
|
 |
| |
While traditional HIV prevention methods remain essential and effective, the epidemic continues.1 We have entered an era of HIV prevention in which the National HIV/AIDS Strategy, clinical studies, and the latest federal and global health guidelines (including those from the CDC and WHO) recognize the importance of a comprehensive prevention approach.2-7 |
|
| |
| |
We at Gilead are inspired by the dedication of healthcare professionals, advocates, and the community, who are on the front line in the nationwide movement to fight HIV. Building on this proactive approach, Gilead will begin to roll out an HIV prevention awareness campaign for healthcare professionals, including educational resources to further enhance HIV prevention efforts. |
|
| |
| |
We look forward to supporting and partnering with you in your continued efforts to help end the HIV epidemic. |
|
| |
| |
Thank you for your dedication,
The Gilead HIV Prevention Team
|
|
| |
| |
CDC=Centers for Disease Control and Prevention; WHO=World Health Organization. |
|
| |
References: 1. Centers for Disease Control and Prevention. Today's HIV/AIDS epidemic. http://www.cdc.gov/nchhstp/newsroom/docs/factsheets/todaysepidemic-508.pdf. Published February 2016. Accessed May 16, 2016. 2. Centers for Disease Control and Prevention. HIV prevention in the United States: new opportunities, new expectations. http://www.cdc.gov/hiv/pdf/policies/cdc-hiv-prevention-bluebook.pdf. Published December 2015. Accessed May 16, 2016. 3. Centers for Disease Control and Prevention. Preexposure prophylaxis for the prevention of HIV infection in the United States–2014: a clinical practice guideline. https://www.cdc.gov/hiv/pdf/PrEPguidelines2014.pdf. Published 2014. Accessed May 5, 2016. 4. World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. http://www.who.int/hiv/pub/guidelines/earlyrelease-arv/en/. Published September 2015. Accessed May 5, 2016. 5. White House Office of National AIDS Policy. National HIV/AIDS strategy for the United States: updated to 2020. https://www.aids.gov/federal-resources/national-hiv-aids-strategy/nhas-update.pdf. Published July 2015. Accessed May 5, 2016. 6. World Health Organization. Programmatic Update Antiretroviral Treatment as Prevention (TasP) of HIV and TB. http://apps.who.int/irisbitstream10665/70904/1/WHO_HIV_2012.12_eng.pdf. Published June 2012. 7. Centers for Disease Control and Prevention. Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV–United States, 2016. http://www.cdc.gov/hiv/pdf/programresources/cdc-hiv-npep-guidelines.pdf. Accessed May 9, 2016.
|
|
| |
| |
Gilead Website | Terms of Use | Privacy Policy | Contact Us
If you would like to stop receiving HIV marketing communications, or if you would like to stop receiving all marketing communications for healthcare professionals from Gilead Sciences, unsubscribe here.
GILEAD and the GILEAD Logo are trademarks of Gilead Sciences, Inc., or its related companies.
© 2016 Gilead Sciences, Inc. All rights reserved. UNBP2339 06/16
333 Lakeside Drive, Foster City, CA 94404
|
|
| |
|
|